Glenzocimab Biosimilar - Research Grade

Human

GP6

>1mg/ml

Fab - G1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q9HCN6

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of glenzocimab, supplied for research use only. It is built around glycoprotein VI (GP6/GPVI, UniProt Q9HCN6), the platelet collagen receptor that the originator drug engages, and is provided as a humanized Fab (IgG1, kappa) fragment mirroring the monovalent format of the originator. It is not the clinical drug and is not intended for human or veterinary use. The molecule is useful as a target-specific reagent for studying GPVI biology and antiplatelet mechanisms in vitro and in defined preclinical systems: as a positive binding control in receptor-interaction and epitope-competition assays, as a benchmarking tool in platelet-function and thrombus-formation studies, and as a reference in biosimilarity, potency, and neutralization workflows. The Fab format is well suited to experiments where bivalent crosslinking or Fc engagement is undesirable. Material is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and can be supplied in bulk milligram-to-gram quantities to support assay development, screening cascades, and preclinical model work requiring consistent lot-to-lot reagent. Glycoprotein VI (GP6/GPVI) is an immunoglobulin-superfamily receptor expressed almost exclusively on platelets and megakaryocytes, where it serves as the major activating receptor for collagen and also engages fibrin and fibrinogen. GPVI associates non-covalently with the FcR gamma-chain, whose ITAM motifs drive Syk-dependent signaling through LAT, PLCgamma2, and downstream calcium mobilization, leading to platelet activation, granule secretion, integrin activation, and thrombus growth. The extracellular region comprises two Ig-like domains (D1 and D2); D2 homotypic interactions promote dimerization that increases avidity for collagen and fibrin. Because GPVI-driven activation is central to arterial thrombosis yet largely dispensable for normal hemostasis, it is an attractive antithrombotic target with a favorable bleeding profile. GPVI is also studied in inflammation, atherosclerosis, and thrombo-inflammatory disease.

GPVI, Glycoprotein 6, Platelet glycoprotein VI

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Glenzocimab biosimilar available in bulk or gram quantities?

A: Yes — the Glenzocimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Glenzocimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Glenzocimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Glenzocimab that binds GP6.